KKKimberley Marie Kendall

Kimberley Marie Kendall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kimberley Marie Kendall has a total of 455 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recalculated CNV penetrance: what it does and does not change for counselling

    by Gerome Breen, Harriet Cullen, Heiko Paland, Evangelos Vassos, Laura Kilarski, Mads E. Hauberg, Boris Chaumette, Sergi Papiol, Donna Duffin, Katherine L. Musliner, et al.

    Goh et al. recently reported that most recurrent copy number variants (CNVs) are far less penetrant for intellectual disability (ID) than previously estimated, and recommended that fourteen should no longer be reported. We show that the lower estimates arise mainly from assuming the population prevalence of ID alone, while case counts derive from broad diagnostic referral cohorts in which about half of individuals were referred for other indications. The proposed formula estimates a risk difference rather than penetrance, and cases and controls were selected, assayed and phenotyped differently. Restricting the outcome to ID also leaves the analysis unable to inform risk for autism, epilepsy, psychiatric, cardiac and other phenotypes. We recommend that families receive phenotype-specific absolute risks for carriers alongside background risks, and that reporting decisions be made locus by locus by guideline bodies, considering all relevant phenotypes. The recalculated estimates inform this debate but are not yet sufficient grounds for changing reporting practice.

  • Open Access

    Genetic predisposition to schizophrenia and circulating proteins in 44,661 UK Biobank participants

    by Rona Strawbridge, David McQueen, Kimberley Kendall, Jana Anderson, Francesco Casanova, Nina Fajs, Etsubdink Gebretsadik, Madeleine Hayman, Frederick Ho, Donald Lyall, et al.

    Schizophrenia (SCZ) is a highly polygenic disorder and is associated with several comorbidities, including depression, cardiovascular disease, and diabetes; yet the biological pathways underlying this clustering remain poorly understood. This study examined associations between a polygenic risk score for SCZ (PRS-SCZ) and circulating protein levels in 44,661 participants of the UK Biobank. We assessed 1,459 proteins (with ≤ 10% missingness) spanning neurological, inflammatory, cardiometabolic, and oncology panels. After adjustment for technical (population structure, genotyping chip), individual (age, sex, lifestyle), and clinical (comorbidities and medication) variables and multiple testing correction, the standardised PRS-SCZ was significantly negatively associated with C2, RNASET2, BTN2A1, CDSN, HLAE, LTA, MICA-MICB, CNTN3, FCER2, INHBC and CPVL concentrations, and positively with ICAM3, BTN3A2, IL5RA, SLAM7 concentrations. These protein biomarkers may provide insights into the biological pathways underlying schizophrenia and/or its comorbidities.

  • Open Access

    Evaluating Wearable Devices for Remote Monitoring in Psychosis: Pilot Study Nested Within the CONNECT Cohort Study.

    by Siân Bladon, John Ainsworth, Roberto Cahuantzi, Matteo Cella, Richard J Drake, Emily Eisner, Richard Emsley, Sophie Faulkner, Kathryn Greenwood, Andrew Gumley, et al.

    Digital remote monitoring technologies, including smartphones and wearables, offer promising avenues for early detection of psychosis relapse. However, selecting devices that are acceptable to participants and produce high-quality data remains challenging. The aim of this nested pilot study was to assess the acceptability and data quality of 3 commercially available wearable devices in people with psychosis recruited to the CONNECT cohort study. Participants recruited to the CONNECT study before July 31, 2024, were included in the pilot study and selected 1 of 3 wearable devices: a Fitbit Charge 5, Samsung Galaxy Watch 5, or Apple Watch SE. Baseline demographics were compared between device groups. Acceptability of devices to participants was assessed through a Wearable Device Satisfaction Questionnaire after 3 months of use, with the proportion of positive responses to each question calculated and compared. Data completeness was also assessed by calculating the number (and percentage) of valid days of step count, heart rate, and sleep data, and comparing between groups. Data quality was assessed through summarizing the amount of troubleshooting required, additional metrics available from the wearables, and continuity of data completeness by calculating the proportion of participants with at least 3 days of heart rate data per week for the first 20 weeks of follow-up. Predefined criteria were used to determine the next steps for the wider CONNECT study: if one device was superior, this would be selected; if none were found to be superior and the Fitbit was found to be noninferior, then Fitbit would be retained. Of the first 107 participants recruited to CONNECT, 105 were included in the pilot study evaluation. The Samsung Galaxy Watch was selected most frequently by participants (46/105, 43.8%), followed by the Apple Watch (27/105, 25.7%), and Fitbit Charge (23/105, 21.9%). Differences in participant demographics were observed across device groups. Self-reported acceptability after use did not differ substantially between devices. However, in terms of data completeness, the median proportion of valid heart rate data days was significantly lower for Samsung Galaxy (median 31.2%, IQR 8.5%-46.0%) compared to Fitbit (median 80.1%, IQR 26.7%-95.0%; P=.003) and Apple Watch (median 49.3%, IQR 21.5%-86.0%; P=.02). There was no significant difference between Fitbit and Apple Watch. Similar patterns were observed for step count and sleep data. The Samsung Galaxy Watch required more frequent troubleshooting for data flow issues and lacked additional physiological metrics, available from the other devices. Due to comparatively lower data quality and technical performance, the Samsung Galaxy Watch was discontinued for use in the subsequent phase of the CONNECT study. The study highlights the importance of incorporating nested evaluations of devices in long-term research.


  • Open Access

    Views of People With Psychosis About Algorithm-Based Relapse Prediction and Data Sharing: Qualitative Study

    by Emily Eisner, Hannah Ball, John Ainsworth, Matteo Cella, Richard J Drake, Daniel Elton, Sophie Faulkner, Kathryn Greenwood, Andrew Gumley, Gillian Haddock, et al.

    Background: Preventing relapses of psychosis is difficult and important. Digital remote monitoring (DRM) systems are being developed and tested to support this. Increasingly, these systems use algorithm-based relapse prediction. Hence, understanding stakeholder views about algorithmic prediction is crucial. Existing qualitative work has explored health professionals’ views, but very few studies have examined the perspectives of people with psychosis on this topic. Objective: This paper aimed to provide an in-depth examination of the views of people with psychosis regarding algorithmic relapse prediction within a DRM system that incorporates active symptom monitoring and passive sensing data. Methods: People with psychosis (n=58) were recruited from 6 geographically distinct areas of the United Kingdom. They participated in semistructured qualitative interviews exploring their views about using a DRM system that predicts psychosis relapse based on a machine learning algorithm. Transcripts were analyzed using reflexive thematic analysis. People with lived experience of psychosis were involved extensively in study design, analysis, and reporting. Results: Findings were described across 4 themes. First, accuracy was a prominent theme. Participants emphasized that transparency about algorithm sensitivity and specificity is crucial and discussed the risks of the relapse prediction algorithm producing false positives (flagging that someone was relapsing when they were not) and false negatives (missing actual relapses). In both cases, participants said that errors may be partially mitigated through a human-in-the-loop approach (theme 2), with DRM blended with human oversight, from clinicians or a dedicated digital monitoring team, and calibrated based on service user, carer, and clinician feedback. The third theme, trust, fears, and choice, noted the interplay between users’ trust in the DRM system and their relationship with the clinical team. This theme described participants’ fears about potential overreactions (hospitalization or excessive medication) or underreactions (no additional support) from the clinical team in response to algorithm-generated relapse predictions. It emphasized the importance of retaining choice around the use of relapse detection algorithms and the sharing of personal data. The final theme described participants’ views about the benefits of using a relapse prediction algorithm , including facilitating early intervention, triaging care according to need, minimizing human bias in assessment, and efficiency in saving staff time. Conclusions: People with psychosis acknowledged potential benefits of algorithm-assisted relapse prediction for receiving timely or efficient care, but with several caveats. Algorithm-generated relapse alerts need to be sufficiently accurate and must be interpreted, with understanding of their limitations, by a trustworthy human who is aware of the relevant context. Algorithm-based relapse predictions should only be used with valid consent, in a way that promotes and respects the autonomy and voice of service users and avoids increasing the use of excessive restriction.


  • Open Access

    The relationship between schizophrenia polygenic scores, blood-based proteins and psychosis diagnosis in the UK Biobank

    by Kimberley M. Kendall, Sophie E. Legge, Eilidh Fenner, Peter Holmans, James Tr Walters

    Despite notable progress in psychiatric genomics, there are no validated blood-based biomarkers for psychosis. Previous studies have failed to establish a link between schizophrenia polygenic scores (PGS) and blood protein levels. We aimed to identify associations between schizophrenia PGS and blood-based proteins, and to determine whether levels of 2077 proteins differ in individuals with psychosis. We analysed proteomic and genomic data from 47,969 participants in the UK Biobank. Association analyses in the 47,678 participants without psychosis (mean age 57.1 years, standard deviation 8.1 years; 54% female) identified nominal associations ( p < 0.05) of schizophrenia PGS with 102 proteins. Four of these (TMPRSS15, ADGRB3, CEACAM21, and KLK1) met the false discovery rate (FDR) threshold of < 0.05. We investigated the association of these four proteins with psychosis in a matched case-control sample (283 cases, 849 controls, mean age 56.9 years, standard deviation 8.4 years; 48% female). In individuals with psychosis, we observed significantly lower levels of KLK1, even after adjusting for potential confounders (effect size −0.25, SE 0.09, FDR 0.049). This direction of effect was opposite to that observed in the primary analysis of individuals without psychosis (effect size 324.67, SE 48.32, FDR 3.85 × 10 −8 ). The effect of antipsychotic medication did not explain this difference. This protein should be taken forward for further study and validation to investigate its potential as a psychosis biomarker.


  • Open Access

    Links between cognition and functioning: Examining the role of mental health in clinically ascertained and population-based samples

    by Amy Joanne Lynham, Kimberley M Kendall, James Tr Walters, Ian R Jones

    Background: Cognitive function is a significant predictor of health and mortality in the population. Common mental health problems, such as depression and anxiety, are associated with both cognitive impairments and increased functional impairment. This study aimed to examine the relationship between cognition, mental health and functioning across two cohorts. Methods: Participants were recruited from an online population cohort, HealthWise Wales (N=3,679), and a psychiatric cohort, the National Centre for Mental Health (NCMH, N=1,036), to complete a cognitive battery and the World Health Organisation Disability Assessment Schedule (WHODAS). We assessed the associations between cognitive performance and the WHODAS, as well as two measures of life functioning: current employment and cohabitation with a partner. We examined the role of current mood, education and health/lifestyle factors using linear and logistic regression. Results: Higher cognitive performance was associated with fewer functional difficulties on the WHODAS (HealthWise Wales: B=-0.12, 95%CI[-0.15,-0.09], P<0.001; NCMH: B=-0.1, 95%CI[-0.13,-0.08], P<0.001), being in employment or education (HealthWise Wales: OR=1.22, 95%CI[1.11,1.34], P<0.001; NCMH: OR=1.31, 95%CI[1.19,1.46], P<0.001) and living with a partner (HealthWise Wales only: OR=1.19, 95%CI[1.06,1.32], P=0.003). Higher levels of depression and anxiety symptoms were consistently associated with reduced functioning across all analyses. The relationship between cognition and functioning remained significant but attenuated after accounting for these symptoms. Conclusions: Cognitive function was associated with functioning in both samples. This association may be partially explained by current symptoms of depression and anxiety. Both cognitive function and common mental health problems may be potential intervention targets to alleviate daily difficulties.

  • Open Access

    The relationship between schizophrenia polygenic scores, blood-based proteins and psychosis diagnosis in the UK Biobank

    by Kimberley M Kendall, Sophie E Legge, Eilidh Fenner, Peter Holmans, James Tr Walters

    Despite notable progress in psychiatric genomics, there are no validated blood-based biomarkers for psychosis. Previous studies have failed to establish a link between schizophrenia polygenic scores (PGS) and blood protein levels. We aimed to identify associations between schizophrenia PGS and blood-based proteins, and to determine whether levels of these proteins differ in individuals with psychosis. We analysed proteomic and genomic data from 49,083 participants in the UK Biobank. Association analyses, excluding individuals with psychosis, identified nominal associations (p < 0.05) of schizophrenia PGS with 109 proteins. Four of these (TMPRSS15, ADGRB3, CEACAM21, and KLK1) met the false discovery rate (FDR) threshold of < 0.05. We investigated the association of these four proteins with psychosis in a matched case-control sample (291 cases, 873 controls). In individuals with psychosis, we observed significantly higher levels of TMPRSS15 (effect size 0.22, standard error 0.07, FDR 6.97 × 10 −3 ) and lower levels of KLK1 (effect size −0.23, SE 0.09, FDR 3.34 × 10 −2 ). These two proteins should be taken forward for further study and validation aimed at investigating their potential as psychosis biomarkers.


  • Open Access

    Copy number variants and their implications for developmental and behavioural problems in cleft lip and/or palate

    by Alexandros Rammos, Rachel Blakey, Charlotte A Dennison, Sarah J Lewis, Nabila Ali, Amy Davies, Yvonne Wren, Kerry Humphries, Jonathan Sandy, Elliott Rees, et al.

    Cleft lip and/or palate (CL/P) is the most common craniofacial congenital anomaly and has been associated with higher risk of neurodevelopmental and behavioural problems indicating potential shared genetic factors between CL/P and neurodevelopmental disorders. In this study, we aimed to determine the prevalence of neurodevelopmental copy number variants (CNV) in children with CL/P and their link to early developmental and behavioural problems. Using data from the Cleft Collective, the largest UK-based national cohort study of children with CL/P, we determined the rates of neurodevelopmental CNVs in children with CL/P comparing them to the general population, explored differences by cleft type and investigated risk of developmental delays and behavioural problems among those with CL/P and neurodevelopmental CNVs. Children with CL/P had a higher prevalence of neurodevelopmental CNVs than participants in four population-based samples (3.7% vs 2.3% in the Avon Longitudinal Study of Parents and Children (ALSPAC), 2.0% in Born in Bradford (BiB), 2.3% in Millenium Cohort Study (MCS), 1.7% in UK Biobank, ORs(95%CIs): ALSPAC = 1.56(1.18–2.06), BiB = 1.84(1.37–2.45), MCS = 1.59(1.19–2.11), UK Biobank = 2.15(1.68–2.71). Children with cleft palate only were 3 times more likely to have a neurodevelopmental CNV (95%CIs1.50–6.59, p = 0.03) than children with cleft lip only. Furthermore, children with CL/P and neurodevelopmental CNVs were more likely to experience early developmental delays and behavioural problems by age 5 compared to children with CL/P and without neurodevelopmental CNVs. These findings highlight that genetic testing ascertaining the presence of neurodevelopmental CNVs might be helpful in early identification of developmental needs in children with CL/P.


  • Open Access

    Psychiatric disorders converge on common pathways but diverge in cellular context, spatial distribution, and directionality of genetic effects

    by Worrawat Engchuan, Omar Shanta, Kuldeep Kumar, Jeffrey R. MacDonald, Bhooma Thiruvahindrapuram, Omar Hamdan, Marieke Klein, Adam Maihofer, James Guevara, Oanh Hong, et al.

    Psychiatric conditions share common genes, but mechanisms that differentiate diagnoses remain unclear. We present a multidimensional framework for functional analysis of rare copy number variants (CNVs) across 6 diagnostic categories, including schizophrenia (SCZ), autism (ASD), bipolar disorder (BD), depression (MDD), PTSD, and ADHD (N = 574,965). Using gene-set burden analysis (GSBA), we tested duplication (DUP) and deletion (DEL) burden across 2,645 functional gene sets defined by the intersections of pathways, cell types, and cortical regions. While diagnoses converge on shared pathways, mixed-effects modeling revealed divergence of pathway effects by cell type, brain region, and gene dosage. Factor analysis identified latent dimensions aligned with clinical axes. A primary factor (F1) captured reciprocal dose-dependent effects of DUP and DEL in SCZ reflecting positive and negative effects in excitatory versus inhibitory neurons and association versus sensory cortex. SCZ and ASD were both strongly aligned with F1 but with opposing directionalities. Orthogonal factors highlighted neuronal versus non-neuronal effects in mood disorders (F2) and differential spatial distributions of DEL effects in ADHD and MDD (F3). High-impact CNVs at 16p11.2 and 22q11.2 were enriched for combinations of cell-type-specific genes involved in pathways consistent with our broader findings. These results reveal molecular and cellular mechanisms that are broadly shared across psychiatric traits but differ between diagnostic categories in context and directionality.


  • Open Access

    Copy Number Variants and their Implications for Developmental and Behavioural Problems in Cleft Lip and/or Palate

    by Alexandros Rammos, Rachel Blakey, Charlotte A Dennison, Sarah J Lewis, Nabila Ali, Amy Davies, Yvonne Wren, Kerry Humphries, Jonathan Sandy, Elliott Rees, et al.

    Cleft lip and/or palate (CL/P) is the most common craniofacial congenital anomaly and has been associated with higher risk of neurodevelopmental and behavioural problems indicating potential shared genetic factors between CL/P and neurodevelopmental disorders. In this study, we aimed to determine the prevalence of neurodevelopmental copy number variants (CNV) in children with CL/P and their link to early developmental and behavioural problems. Using data from the Cleft Collective, the largest UK-based national cohort study of children with CL/P, we determined the rates of neurodevelopmental CNVs in children with CL/P comparing them to the general population, explored differences by cleft type and investigated risk of developmental delays and behavioural problems among those with CL/P and neurodevelopmental CNVs. Children with CL/P had a higher prevalence of neurodevelopmental CNVs than participants in four population-based samples (3.7% vs 2.3% in the Avon Longitudinal Study of Parents and Children (ALSPAC), 2.0% in Born in Bradford (BiB), 2.3% in Millenium Cohort Study (MCS), 1.7% in UK Biobank, ORs(95%CIs): ALSPAC= 1.56(1.18-2.06), BiB= 1.84(1.37-2.45), MCS= 1.59(1.19-2.11), UK Biobank= 2.15(1.68–2.71). Children with cleft palate only were 3 times more likely to have a neurodevelopmental CNV (95%CIs1.50-6.59, p=0.03) than children with cleft lip only. Furthermore, children with CL/P and neurodevelopmental CNVs were more likely to experience early developmental delays and behavioural problems by age 5 compared to children with CL/P and without neurodevelopmental CNVs. These findings highlight that genetic testing ascertaining the presence of neurodevelopmental CNVs might be helpful in early identification of developmental needs in children with CL/P.